HIV 1 News and Research

RSS

Clinical trial to evaluate maraviroc-based PrEP regimens for HIV prevention

Scientists are launching the first clinical trial to test whether drug regimens containing maraviroc, a medication currently approved to treat HIV infection, are also safe and tolerable when taken once daily by HIV-uninfected individuals at increased risk for acquiring HIV infection. The eventual goal is to see if the drug regimens can reduce the risk of infection.

19 Jul 2012

Report shows high rates of HIV infections and deaths from AIDS among Black MSM

Today, the Black AIDS Institute released its latest report, Back of the Line: The State of AIDS Among Black Gay Men in America. The landmark report highlights alarming data that show disproportionately high rates of HIV infections and deaths from AIDS among Black MSM, why the disparities persist and are growing worse, and the urgent need for local and national leadership to immediately address the devastating health crisis.

19 Jul 2012

Duke receives Gates Foundation grant for HIV vaccine study

The Bill & Melinda Gates Foundation has awarded a new grant to Duke University Medical Center for work developing vaccines that can induce IgA antibodies for preventing HIV-1 infection. This award comes from the Gates' Collaboration for AIDS Vaccine Discovery (CAVD) program.

19 Jul 2012

Researchers identify new behavior for the human macrophage

Researchers at the Institute of Human Virology of the University of Maryland School of Medicine have identified a new behavior for the human macrophage that provides new explanations for several features of HIV biology, including how the virus persists within the body indefinitely, how quiescently infected CD4+ T-cells arise, and how the infection leads to depletion of CD4+ T-cells.

19 Jul 2012

Truvada gains FDA approval as HIV preventive

The daily pill is the first aimed at reducing the risk of contracting HIV in healthy people who are at high risk of contracting AIDS. It will have a boxed warning that it should be used only by people whose HIV-negative status is confirmed prior to prescription and at least every three months after.

18 Jul 2012

New roadmap provides expert guidance on how to reduce racial and ethnic health disparities

Major disparities exist along racial and ethnic lines in the United States for various medical conditions, but guidance is scarce about how to reduce these gaps. Now, a new "roadmap" has been unveiled to give organizations expert guidance on how to improve health equity in their own patient populations.

18 Jul 2012

Podcast examines HIV/AIDS economics, U.S. role in global epidemic response

In this Center for Global Development (CGD) "Global Prosperity Wonkcast," Lawrence MacDonald, vice president for communications and policy outreach at CGD, interviews CGD senior fellow Mead Over, an expert on the economics of the HIV/AIDS epidemic, and Jenny Ottenhoff, CGD policy outreach associate, about the "state of the epidemic, budget austerity, and the U.S. role in the global response."

18 Jul 2012

Advocates, policy experts respond to FDA approval of Truvada for HIV prevention

Though the FDA's Monday approval of the antiretroviral drug Truvada for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection among people at risk of contracting the virus "was hailed by many as an important step in the fight against AIDS, concerns that people will incorrectly use the drug -- potentially spurring drug resistance -- led others to blast the agency for not laying down tougher rules," the Wall Street Journal's "Health Blog" writes.

18 Jul 2012

FDA approves Truvada as HIV prevention strategy for high-risk, uninfected individuals

The FDA on Monday announced the approval of the first drug for pre-exposure prophylaxis (PrEP) to prevent HIV among people at risk of contracting the virus, "which some are calling a landmark in the fight against AIDS," ABC News reports.

18 Jul 2012

Combination prevention strategy trials to start later this year in Africa, GlobalPost reports

As part of its "AIDS Turning Point" series, GlobalPost examines how the United States and its African partners are designing clinical trials at four African sites to test whether a combination of prevention methods and strategies -- "notably the vaccine-like preventative effect on transmission when someone starts taking AIDS drugs, as well as the life-long protection afforded to many due to male circumcision" -- could "put them on the road to a Holy Grail: the numbers of HIV infections tumbling down."

18 Jul 2012

Researchers assess novel approach to encourage HIV positive people to seek care and treatment

In a new study by ICAP at Columbia's Mailman School of Public Health, researchers are assessing a novel approach to encourage newly diagnosed HIV positive people to seek care and adhere to HIV treatment.

18 Jul 2012

First Edition: July 18, 2012

Today's headlines include coverage of a new report that offers a gloomy fiscal forecast for states as they confront rising health care costs, underfunded pensions and a range of other economic challenges.

18 Jul 2012

Advocates in Sri Lanka call for change to laws that criminalize, stigmatize sex work, same-sex relationships

"Sri Lanka has long enjoyed a low 0.1 percent HIV prevalence but, as the number of fresh infections rises steadily, experts are calling for a change in the country's archaic laws that make sex work illegal and criminalizes homosexual activity," Inter Press Service reports.

18 Jul 2012

Specific therapy may cut pneumonia mortality in HIV babies

The high mortality rate associated with acute severe pneumonia-related respiratory failure in infants exposed to or infected with HIV can be reduced to 30% if a treatment plan involving antibiotics, ventilation, and fluid restriction is used, researchers report.

17 Jul 2012

Johnson & Johnson second quarter sales decrease 0.7% to $16.5B

Johnson & Johnson today announced sales of $16.5 billion for the second quarter of 2012, a decrease of 0.7% as compared to the second quarter of 2011. Operational results increased 3.5% and the negative impact of currency was 4.2%.

17 Jul 2012

First Edition: July 17, 2012

Today's headlines include a report that concludes that few Americans will pay more as a result of the health law.

17 Jul 2012

Duke University to receive CHAVI-Immunogen Discovery grant for effective HIV vaccine

A large federal grant awarded to Duke University will fund a highly focused program to discover how to induce the precise immune factors needed for effective vaccines against HIV.

17 Jul 2012

U.S. FDA approves Gilead’s Truvada to minimize risk of sexually-acquired HIV infection

Today, the U.S. Food and Drug Administration approved Truvada (emtricitabine/tenofovir disoproxil fumarate), the first drug approved to reduce the risk of HIV infection in uninfected individuals who are at high risk of HIV infection and who may engage in sexual activity with HIV-infected partners. Truto reduce the risk of sexually-acquired HIV infection in adults at high risk.

17 Jul 2012

Viewpoints: 'Tug of War' over Medicaid expansion; Bill Keller debunks 5 'Obamacare' myths

The new health care law's individual mandate -; the provision pushing people to buy insurance, and upheld last month by the Supreme Court -; has garnered huge attention. But about half the planned expansion of insurance coverage under the new law comes from another source entirely: growth of the Medicaid program. Yet Medicaid has never been especially popular, and when its expanded role becomes more widely understood, it is likely to become less popular still.

17 Jul 2012

Drug treatments, scientific advances fuel hope for HIV control as AIDS 2012 conference draws near

"A cure for AIDS remains a distant prospect but a host of drug treatments and other advances have fueled fresh hope that new HIV infections may someday be halted for good," Agence France-Presse reports.

17 Jul 2012

HIV 1 News and Research

Clinical trial to evaluate maraviroc-based PrEP regimens for HIV prevention

Report shows high rates of HIV infections and deaths from AIDS among Black MSM

Duke receives Gates Foundation grant for HIV vaccine study

Researchers identify new behavior for the human macrophage

Truvada gains FDA approval as HIV preventive

New roadmap provides expert guidance on how to reduce racial and ethnic health disparities

Podcast examines HIV/AIDS economics, U.S. role in global epidemic response

Advocates, policy experts respond to FDA approval of Truvada for HIV prevention

FDA approves Truvada as HIV prevention strategy for high-risk, uninfected individuals

Combination prevention strategy trials to start later this year in Africa, GlobalPost reports

Researchers assess novel approach to encourage HIV positive people to seek care and treatment

First Edition: July 18, 2012

Advocates in Sri Lanka call for change to laws that criminalize, stigmatize sex work, same-sex relationships

Specific therapy may cut pneumonia mortality in HIV babies

Johnson & Johnson second quarter sales decrease 0.7% to $16.5B

First Edition: July 17, 2012

Duke University to receive CHAVI-Immunogen Discovery grant for effective HIV vaccine

U.S. FDA approves Gilead’s Truvada to minimize risk of sexually-acquired HIV infection

Viewpoints: 'Tug of War' over Medicaid expansion; Bill Keller debunks 5 'Obamacare' myths

Drug treatments, scientific advances fuel hope for HIV control as AIDS 2012 conference draws near

Decoding Cannabis: Differentiating Hemp and Marijuana

Deciphering the Microbiome with The Microsetta Initiative

Leveraging the power of automation to boost research

Latest News